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Abstract
Background New evidence is emerging on the importance of lean body mass during periods of illness and recovery. The
preservation of lean body mass during such periods of intense stress impacts both patient and treatment outcomes. However,
data concerning the incidence of sarcopenia among older people during hospitalization are scarce. The objective of this study
was to evaluate the development of sarcopenia in a sample of hospitalized older subjects.
Methods We used data of 394 participants from the multicentre Italian Study conducted by the Gruppo Lavoro Italiano
Sarcopenia—Trattamento e Nutrizione (GLISTEN) in 12 Acute Care Wards (Internal Medicine and Geriatrics) of University
Hospitals across Italy. This study was designed to determine the prevalence of sarcopenia at hospital admission and the
change in muscle mass and strength during hospitalization. Sarcopenia was defined as low skeletal mass index (kg/m2) along
with either low handgrip strength or slow walking speed [European Working Groups on Sarcopenia in Older People (EWGSOP)
criteria]. Estimation of skeletal muscle mass was performed by bioelectrical impedance analysis (BIA).
Results The mean age of the 394 enrolled patients (including 211 females who accounted for 53% of the sample) was
79.6 ± 6.4 years. Among those without sarcopenia at hospital admission, 14.7% of the study sample met the EWGSOP
sarcopenia diagnostic criteria at discharge. The incidence of sarcopenia during hospitalization was significantly associated with
the number of days spent in bed but was not correlated with the total length of hospital stay. In particular, patients who
developed sarcopenia spent an average of 5.1 days in bed compared with 3.2 days for those with no sarcopenia at discharge
(P = 0.02). Patients with sarcopenia showed a significantly lower body mass index compared with non-sarcopenic peers
(25.0 ± 3.8 kg/m2 vs. 27.6 ± 4.9 kg/m2, respectively; P< 0.001). Similarly, the skeletal mass index at admission was significantly
lower among patients who developed sarcopenia during hospital stay.
Conclusions Incident sarcopenia during hospital stay is relatively common and is associated with nutritional status and the
number of days of bed rest.
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Introduction
Sarcopenia is one of the most important risk factors for
mobility impairment, falls, disability, loss of independence,
hospitalization, and death among older people.1 The concept
of sarcopenia is encountered increasingly often in research
and clinical practice, not only in geriatric medicine but also
in other specialties.1 New evidence is emerging on the
importance of lean body mass during periods of illness and
recovery.2 Sarcopenia is considered a geriatric syndrome
described as the impairment of muscle function due to the
loss of skeletal muscle mass, which occurs during the
aging process.3,4
The clinical implications of sarcopenia have been
consistently described across different settings, including
community dwelling samples, nursing homes, and acute care
units.5,6 According to a recent systematic review, the
prevalence of sarcopenia is significantly high in most of the
geriatrics settings, but estimations impressively vary across
studies because of different population characteristics,
diagnostic criteria, and methods used to assess muscle mass
and physical performance. When assessed according to the
European Working Groups on Sarcopenia in Older People
(EWGSOP) criteria,7 prevalence rates range from 1 to 29%
among community-dwelling populations and from 17.4 to
32.8% among institutionalized persons.8 More recently,
Bianchi and colleagues9 demonstrated that among older
Italian patients admitted to hospital, sarcopenia, defined
according to the EWGSOP criteria,7 was very common,
and its prevalence raised steeply with increasing age in
both genders.
Data concerning the incidence of sarcopenia among older
people during hospital stay are scarce. In older patients,
besides the negative effect of the acute event, hospitalization
itself might represent an additional stressor in terms of
reduced caloric intake, extremely low physical activity, or
prolonged bed rest. For example, experimental studies
suggest that in healthy older people, prolonged bed rest is
associated with significant decrease in muscle protein
synthesis, lower extremity lean mass, and strength.10,11 The
aim of this study was to evaluate the onset of sarcopenia in
a sample of hospitalized older patients. We conducted a
multicentre observational study of older patients admitted
to 12 acute care wards in Italy. The primary objective of this
study was to estimate the incidence and the clinical
correlates of sarcopenia in a large sample of hospitalized
older patients without sarcopenia at the time of hospital
admission.
Methods
Data are from the Gruppo Lavoro Italiano Sarcopenia—
Trattamento E Nutrizione (GLISTEN) project, an observational
study performed in geriatric and internal medicine acute care
wards of 12 Italian hospitals (Monza, Turin, Ferrara, Verona,
Parma, Florence, Ancona, Rome, Napoli I, Napoli II, Cagliari,
Messina). Methodology of the GLISTEN project has been
described in detail elsewhere.9 In brief, the study was
designed to investigate the prevalence and clinical correlates
of sarcopenia in older hospitalized patients in Italy and to
estimate the incidence of sarcopenia during hospital stay.
All participating centres obtained ethical approval from their
institutions, and all participants signed a written consent.
Study design, data collection, and sample
All patients aged 65 years or more (n = 655) consecutively
admitted to participating wards from February 2014 to May
2014 entered the study protocol. The only exclusion criterion
was the unwillingness to take part to the study. For the
present study, we included only patients without sarcopenia
at baseline assessment (n = 428). Six patients died during
the hospital stay, and 28 were not included for missing values
in the variables of interest. The final sample was therefore
comprised of 394 participants (Figure 1).
All patients were assessed within the first 2 days of hospital
admission and followed until discharge (within 24 h of
hospital discharge). Participants underwent comprehensive
geriatric assessment (CGA), including demographic
characteristics, functional status, cognitive and mood
assessment, medications use, admission and discharge
diagnoses, and biochemical tests. A variety of information
sources, such as direct observation, interviews with the
patient, family, friends or formal service providers, and
review of clinical records, both medical and nursing, were
used. Finally, objective measurers of physical performance
(handgrip strength and 4 m usual walking speed test) were
assessed at hospital admission and before discharge.
Assessment of sarcopenia
Sarcopenia was defined, according to EWGSOP criteria, as the
presence of low muscle mass plus low muscle strength or low
physical performance.7
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Muscle mass was measured by bioelectrical impedance
analysis (BIA). Bioelectrical impedance analysis resistance
(Ohms, Ω) was obtained using a Quantum/S Bioelectrical
Body Composition Analyser (Akern Srl, Florence, Italy) with
an operating frequency of 50 kHz at 800 mA. Whole-body
BIA measurements were taken between the right wrist and
ankle with the patient in a supine position.12 Muscle mass
was estimated using the equation developed by Janssen
and colleagues13,14:
skeletal muscle mass kgð Þ ¼ height2=BIA resistance
0:401Þ þ gender3:825ð Þ
þ age 0:071ð Þ þ 5:102;
where height is measured in cm; BIA resistance is
measured in Ω; for gender, men = 1 and women = 0;
and age is measured in years. This BIA equation
was developed and cross-validated against magnetic
resonance imaging measures of whole-body muscle mass.
The skeletal muscle index [SMI (kg/m2)] was obtained
dividing absolute muscle mass by squared height.14 Using
the cutoffs indicated in the EWGSOP consensus paper,7 low
muscle mass was classified as SMI less than 8.87 and
6.42 kg/m2 in men and women, respectively. These cutoffs
were similar to those obtained among 2276 elderly women
and 2223 elderly men from the Third National Health and
Nutrition Examination Survey (NHANES III).15,16
Muscle strength was assessed by grip strength, measured
using a hand-held dynamometer (JAMAR hand dynamometer
Model BK-7498, Fred Sammons Inc., Brookfield, IL). Three
trials for each hand were performed, and the highest value
of the strongest hand was used in the analyses. BMI-adjusted
values were used to identify low muscle strength. Cut-points
were similar to those obtained among 469 men and 561
Figure 1 Application of the EWGSOP algorithm for sarcopenia case finding in the GLISTEN sample.
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women (age range from 20 to 102 years) from the InCHIANTI
study population.17
Walking speed was evaluated measuring participants’
usual gait speed (in meters per second) over a 4 m course.
A cutoff point of 0.8 m/s or less identified participants with
low physical performance.7
Covariates
Socio-demographic variables (age, gender, smoking habit,
education) were assessed through clinical interview at hospital
admission. Functional status in basic activities of daily living
(ADL) was measured according to the participants’ self-reported
difficulty in performing each of six activities: getting in and out
of a bed, bathing, dressing, eating, continence, and using the
toilet. Severe ADL disability was defined as the presence of
difficulty in three or more activities.18 Cognitive functioning
was assessed using the Short Portable Mental Status
Questionnaire.19 Patients with scores≥ 3 were considered to
be cognitively impaired. Depression was assessed by means of
the 15-item Geriatric Depression Scale, where the cutoff
of> 5 points suggests significant depressive symptoms.20
During hospital stay, days of bed rest were considered those
spent in the bed for 24 h. The days of fasting were considered
according to the non-consumption of at least two main meals.
Diagnoses of specific medical conditions were gathered
from the patient, attending physicians, and by a careful
review of medical charts; comorbidity was assessed using
the Charlson Comorbidity Index by adding scores assigned
to specific discharge diagnoses. Assessors recorded all drugs
currently taken by the participants at admission: brand name,
formulation, and daily dosage were registered. All drugs were
coded according to the Anatomical Therapeutic and Chemical
codes. The number of drugs taken was also calculated.
Statistical analysis
For the present study, we selected all patients without
sarcopenia at baseline (hospital admission). After excluding
six patients who died during hospital stay and 28 for missing
values, the final sample was composed of 394 participants.
Patients with incident sarcopenia during hospital stay were
identified using the algorithm developed by the EWGSOP7
for sarcopenia case-finding and screening in practice
(Figure 1). Data were analysed to obtain descriptive statistics.
Continuous variables are presented as mean ± standard
deviation. Differences in socio-demographic, functional, and
clinical characteristics between patients with or without
incident sarcopenia were analysed in different ways.
Quantitative parameters with normal distribution were
tested by one-way analysis of variance, after a pretest for
homogeneity of variances. If distribution was not normal,
the non-parametric Kruskal–Wallis rank test was used.
Categorical variables were analysed by the χ2 test. A P value
lowers than 0.05 was chosen for statistical significance.
The relationship between incident sarcopenia and clinical
and functional variables was estimated by deriving odds
ratios (ORs) from multiple logistic regression models.
Sarcopenia was included as the dependent variable in such
models. Based on previous researches, we considered age,
gender, length of hospital stay, functional ability (ADL score),
cognitive performance, comorbidity, and BMI as factors
potentially associated with incident sarcopenia and included
them as independent variables in the models. We provide
estimates of association while adjusting for potential
confounders by deriving crude and adjusted ORs and the
corresponding 95% confidence intervals (CIs) from these
models. All analyses were performed using SPSS software
(version 11.0, SPSS Inc., Chicago, IL).
Results
The mean age of the 655 enrolled patients in the GLISTEN
study (including 340 females who accounted for 51.9% of
the sample) was 81.0 ± 6.8 years (82.3 ± 6.6 and 79.6 ± 6.0,
in women and men, respectively). Sarcopenia at hospital
admission was diagnosed in 227 (34.7%) patients (Figure 1).
Among patients without sarcopenia at hospital admission
(n = 394), 58 participants (14.7%) met the EWGSOP
sarcopenia diagnostic criteria at hospital discharge (Figure
1). More than 50% of those who developed sarcopenia
during hospital stay showed over 10% muscle mass loss
compared with baseline values.
Patients who developed sarcopenia (Table 1) were
significantly older than those who did not (82.0 ± 7.2 vs.
79.2 ± 6.2 years, respectively; P < 0.01). Participants with
incident sarcopenia during hospital stay showed significantly
lower baseline BMI compared with patients who did not
develop sarcopenia (25.0 ± 3.8 kg/m2 vs. 27.6 ± 4.9 kg/m2,
respectively; P < 0.001). Similarly, SMI at hospital admission
was significantly lower among patients who developed
sarcopenia during hospital stay (8.4 ± 1.5 kg/m2 vs.
9.0 ± 1.8 kg/m2, respectively; P = 0.01). Participants with
greater impairments in daily activities (by means ADL score)
and cognitive performance (according to the SPMSQ score)
showed higher incidence of sarcopenia at discharge. Finally,
the incidence of sarcopenia during hospitalization was
significantly associated with the number of days spent in
bed, while it was only marginally correlated with the total
length of hospital stay. In particular, patients with incident
sarcopenia spent an average of 5.4 ± 6.7 days in bed (more
than 28% of the length of hospital stay) compared with
3.2 ± 5.3 days (18% of the length of hospital stay) among
participants without sarcopenia at discharge (P = 0.02).
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After multivariable adjustment, (Table 2) we found an
increased and independent likelihood of developing
sarcopenia during hospital stay with ADL disability (OR:
1.23; 95% CI 1.01–1.49) and length of bed rest (OR: 1.05;
95% CI 1.01–1.12). Conversely, a decreased probability of
being sarcopenic at hospital discharge was detected with
increasing BMI (OR: 0.92; 95% CI 0.86–0.98) and baseline
SMI (OR: 0.43; 95% CI 0.29–0.61).
Discussion
The evaluation of the impact of hospitalization on the onset of
sarcopenia among frail older patients is an important and
intricate issue. In the present study, we explored the
incidence of sarcopenia during hospital stay and the
association of different domains with incident sarcopenia in
a large sample of hospitalized older patients. Our data show
that sarcopenia develops in approximately 15% of
hospitalized elderly patients. Considering that, at the time of
hospital admission, the prevalence of sarcopenia is around
35%;9 this means that half of the patients present with
sarcopenia at discharge. Furthermore, our findings show that
the days of bed rest and baseline disability exert an important
influence on the onset of sarcopenia, independent of age,
gender, and other clinical and functional variables. Greater
muscle mass and good nutritional status at hospital admission
emerged as protective factors against incident sarcopenia.
Table 2 Unadjusted and adjusted models for risk of incident sarcopenia in the study population.
Univariate odds ratio (95% CI) Adjusted modela odds ratio (95% CI)
Age, years 1.07 (1.02–1.11) 1.03 (0.98–1.09)
Gender (female) 0.84 (0.48–1.47) 0.86 (0.46–1.49)
Cognitive impairment (SPMSQ) 1.21 (1.08–1.35) 1.03 (0.97–1.32)
ADL impairment (number) 1.23 (1.08–1.41) 1.23 (1.01–1.49)
Body mass index (kg/m2) 0.88 (0.82–0.94) 0.92 (0.86–0.98)
Skeletal muscle index (kg/m2) 0.81 (0.68–0.96) 0.43 (0.29–0.61)
Emergency admission 2.03 (1.05–3.91) 1.25 (0.59–2.67)
Length of hospital stay (days) 1.03 (1.00–1.05) 0.99 (0.95–1.03)
Length of bed rest (days) 1.05 (1.00–1.09) 1.05 (1.01–1.12)
aAdjusted simultaneously for all the variables listed.
Age, SPMSQ score, ADL scale score, BMI, skeletal muscle index, emergency admission, length of hospital stay, and length of bed rest were
treated as a continuous variable.
Table 1 Selected general characteristics and comorbidities of study participants according to the incidence of sarcopenia
Incidence of sarcopenia
Characteristics Total sample (n = 394) No (n = 336) Yes (n = 58) P-value
Age, mean ± SD 79.6 ± 6.4 79.2 ± 6.2 82.0 ± 7.2 0.002
Female, n (%) 211 (53.6) 182 (54.2) 29 (50.0) 0.32
BMI, mean ± SD 27.2 ± 4.9 27.6 ± 4.9 25.0 ± 3.8 <0.001
Emergency admission, n (%) 256 (65.1) 211 (63.0) 45 (77.6) 0.02
ADL score, mean ± SD 1.3 ± 1.8 1.2 ± 1.7 2.1 ± 2.3 0.001
Severe ADL disability, n (%) 87 (22.1) 65 (19.3) 22 (37.9) 0.02
GDS, mean ± SD 4.9 ± 3.6 4.9 ± 3.6 4.5 ± 3.5 0.45
SPMSQ, mean ± SD 2.3 ± 2.9 2.1 ± 2.0 3.3 ± 2.9 <0.001
Number of drugs, mean ± SD 6.0 ± 3.0 6.0 ± 3.0 6.0 ± 2.7 0.920
Charlson Comorbidity Index, mean ± SD 3.1 ± 2.3 3.1 ± 2.3 3.0 ± 2.1 0.63
Hypertension, n (%) 294 (74.6) 256 (76.2) 38 (65.5) 0.06
CHD, n (%) 104 (26.4) 86 (25.6) 18 (31.0) 0.23
CHF, n (%) 56 (14.2) 46 (13.7) 10 (17.2) 0.29
Diabetes, n (%) 126 (32.0) 114 (33.9) 12 (20.7) 0.03
COPD, n (%) 99 (25.1) 82 (24.4) 17 (29.3) 0.26
Stroke, n (%) 41 (10.4) 35 (10.4) 6 (10.3) 0.61
Cancer, n (%) 51 (12.9) 41 (12.2) 10 (17.2) 0.19
Serum albumin, mean ± SD 3.6 ± 0.7 3.6 ± 0.7 3.5 ± 0.6 0.29
Haemoglobin, mean ± SD 11.9 ± 2.2 11.9 ± 2.2 11.9 ± 2.1 0.79
Length of hospital stay (days), mean ± SD 10.2 ± 8.1 9.9 ± 7.6 12.1 ± 10.3 0.05
Length of bed rest (days), mean ± SD 3.5 ± 5.6 3.2 ± 5.3 5.1 ± 6.7 0.02
Days of fasting, mean ± SD 0.3 ± 0.9 0.3 ± 0.8 0.5 ± 1.5 0.09
SMI at admission (kg/m2), mean ± SD 8.9 ± 1.8 9.0 ± 1.8 8.4 ± 1.5 0.01
CHD, coronary heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; SMI, skeletal muscle index.
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Sarcopenia is caused by the simultaneous reduction in the
number of muscle fibres and atrophy of the remaining
myocytes, likely as a result of lower rate of myofibrillar
protein synthesis and enhanced myonuclear elimination via
an apoptosis-like mechanism.21,22 These phenomena reflect
a progressive reduction of anabolism and increased
catabolism, along with reduced muscle regeneration capacity.
Histological sections of aged muscles have also shown
increased infiltration of non-contractile tissue (i.e. collagen
and fat).23
Muscle mass loss is linked, although not linearly, with
reduced force generation and impaired muscle
performance.24 Many factors are involved in the age-
dependent muscle decline: the aging processes itself,
genetic susceptibility, behavioural factors (e.g. less-than-
optimal diet, prolonged bed rest, sedentary lifestyle),
chronic health conditions, and several drugs.5 In this
respect, it is important to highlight that our results show
that the days of inactivity are an important risk factor for
the onset of sarcopenia. On the other hand, in agreement
with previous observations,25 we found a significant
association between baseline BMI and SMI value the
incidence of sarcopenia, with patients with higher BMI
and greater SMI having a lower likelihood of developing
sarcopenia during hospital stay. Malnutrition per se is a
powerful risk factor for sarcopenia and might well explain
the increased prevalence and incidence of sarcopenia
in patients with lower BMI.26 Loss of appetite
and/or reduction of food intake, usually observed during
hospitalization, can lead to muscle wasting, decreased
immunocompetence, and an increased rate of disease
complications. In particular, a reduction in food intake along
with physical inactivity leads to significant losses in muscle
mass and strength.27
Muscle composition and function are regulated by
muscle protein turnover rate. Impaired muscle protein
synthesis may be due to many factors including inadequate
nutritional intake, deficit in post-absorptive protein
synthesis, and reduced anabolic response to nutrient
ingestion, especially amino acids.28,29 It has been shown
that physical exercise and targeted oral nutritional
supplementation may improve muscle health through
various mechanisms.30
Our findings have potentially relevant clinical implications.
Physical inactivity during in-hospital bed rest and
malnutrition can have a negative synergistic effect on muscle
protein synthesis, favouring the subsequent onset of
sarcopenia. The preservation of muscle mass and function is
increasingly recognized as a crucial factor for promoting
healthy aging and better outcomes in different healthcare
settings. As such, sarcopenia represents an ideal target for
interventions aimed at preventing or postponing the
occurrence of negative health-related events in late life. At
present, multicomponent interventions, involving the
combination of physical activity and nutrition (in particular
adequate protein intake) are the only ‘interventions’ to
prevent negative outcomes.30 In particular, an adequate
nutritional support and an early mobilization program during
hospital stay are essential for preventing sarcopenia. For this
reason, it is very important to promptly arrange rehabilitation
services for frail older inpatients to avoid bed immobilization
and treat potentially disabling conditions. Programs that
meet these needs can reduce the number of severely
disabled persons, or at least delay their entering a critically
disabled state.
In interpreting our findings, some limitations should be
considered. First, as in all observational studies, results
may be confounded by unmeasured factors. However, our
homogeneous population of hospitalized older people
minimizes the possibility that patients without sarcopenia
at hospital discharge had substantially better healthcare
or health knowledge than those with incident sarcopenia.
However, because of the use of an extensive
multidimensional assessment approach, the present study
could comprehensively investigate the different domains
influencing the incidence of sarcopenia. This made it
possible to control for a large number of potential
confounders. Despite this effort, it is still possible that
differences between study groups may have biased the
results and conclusions. For example, biomarkers that
potentially correlate with sarcopenia (i.e. vitamin D and
inflammatory markers) were not considered. Second, the
use of BIA for muscle mass assessment presents some
drawbacks mainly due to hydration problems frequently
observed in older persons that may result in
underestimation of body fat and overestimation of fat-free
mass. On the other hand, BIA is inexpensive, easy to use,
readily reproducible, and appropriate for both ambulatory
and bedridden patients, considered as a portable
alternative to dual energy X-ray absorptiometry.31,32 As
such, its standardized use may favour the widespread
assessment of body composition in everyday clinical
practice.33 Another important limitation that needs to be
considered in the interpretation of the results is the lack
of data about daily food intake. Even though the days of
fasting did not significantly differ between patients who
developed sarcopenia and those who did not, it is possible
that the intake of specific nutrients (e.g. protein intake or
oral supplementation) might be different. Finally, we were
not able to formally differentiate cases of sarcopenia from
cases of cachexia, a condition highly prevalent in acute care
wards. Although after the exclusion of cases with very low
BMI (< 20 kg/m2), the prevalence of sarcopenia at hospital
admission was not substantially modified (31.9%), the
possibility cannot be ruled out that we overestimated the
true prevalence of sarcopenia.9
Despite these limitations, our data support the concept
that there is an urgent need to screen for sarcopenia at
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an early stage—for example, at hospital admission and/or
during hospital stay—to initiate prevention and specific
interventions to avoid the debilitating consequences of this
condition. For the construction of a practical conceptual
model, sarcopenia may be considered the central element
of the physical frailty syndrome.34,35 By establishing a
specific biological basis (i.e. skeletal muscle decline) of
physical frailty, new approaches may be determined for
the development of interventions designed to reduce or
reverse this disorder.36,37
In conclusion, the results of this study show that the
number of patients who develop sarcopenia during
hospitalization is relatively high. The onset of sarcopenia is
directly related to the nutritional status and the number of
days of bed rest. This is of particular interest considering that
during a period of acute illness, the loss of lean body mass
can both affect the patient’s recovery outcomes and
treatment plans. Preventing the loss of muscle mass during
hospitalization, through specific nutritional programs and
early mobilization, might improve disease-specific and
functional outcomes.38,39
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